Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13748259 | 0.80 | HTR2A (0.39) | GLP1RHTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL13748225 | 0.80 | HTR2A (0.39) | GLP1RHTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL19365963 | 0.78 | ALDH1A1 (0.39) | GLP1RHTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL19425821 | 0.78 | ALDH1A1 (0.40) | ALDH1A1MAPTMAPK1NPSR1KDM4E | |
| SCHEMBL12985509 | 0.77 | CYP3A4 (0.38) | HTR2AHTR2CHTR2BALDH1A1LMNA | |
| SCHEMBL16132832 | 0.76 | HTR2A (0.42) | GLP1RHTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL13748804 | 0.76 | NPC1 (0.40) | ALDH1A1LMNAMAPTMAPK1KDM4E | |
| SCHEMBL5783110 | 0.76 | ALDH1A1 (0.43) | GLP1RALDH1A1KDM4EPOLBCYP2C19 | |
| SCHEMBL14550204 | 0.76 | GAA (0.40) | GLP1RHTR2AALDH1A1G6PDPOLB | |
| SCHEMBL12985782 | 0.75 | KDM4E (0.46) | ALDH1A1LMNAMAPTMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-8835423-B2 | Azepine inhibitors of janus kinases | INCYTE CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| US-8563541-B2 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | GLP1R 3533/4885HTR2A 3849/4885HTR2C 3835/4885 |
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | GLP1R 598/4885HTR2A 4760/4885HTR2C 4434/4885 |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | GLP1R 598/4885HTR2A 4760/4885HTR2C 4434/4885 |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | GLP1R 3533/4885HTR2A 3849/4885HTR2C 3835/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | GLP1R 3533/4885HTR2A 3849/4885HTR2C 3835/4885 |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | GLP1R 3533/4885HTR2A 3849/4885HTR2C 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.